Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer

Noem&iacute; Reguart1, Andr&eacute;s Felipe Cardona2, Rafael Rosell31Medical Oncology Service, ICMHO, Hospital Clinic Barcelona, Barcelona, Spain; 2Clinical and Translational Oncology Group, Institute of Oncology, Fundaci&oacute;n Santa Fe de Bogot&aacute;, Bogot&...

Full description

Bibliographic Details
Main Authors:	Noem&iacute; Reguart, Andr&eacute;s Felipe Cardona, Rafael Rosell
Format:	Article
Language:	English
Published:	Dove Medical Press 2010-06-01
Series:	Cancer Management and Research
Online Access:	http://www.dovepress.com/role-of-erlotinib-in-first-line-and-maintenance-treatment-of-advanced--a4534

Similar Items

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
by: Vergnen&egrave;gre A, et al.
Published: (2012-01-01)

Prolonged response to first-line erlotinib for advanced lung adenocarcinoma
by: Copeman Michael
Published: (2008-11-01)

Clinical Observation of Erlotinib as the First-line Treatment for Patients with Advanced Non-small Cell Lung Cancer
by: Yunjian HUANG, et al.
Published: (2009-12-01)

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
by: Walleser S, et al.
Published: (2012-09-01)

Erlotinib in the Second/Third Line Treatment of Patients with Advanced Non-small Cell Lung Cancer
by: Yilong WU, et al.
Published: (2009-05-01)

A Case Report of Erlotinib as First-line Therapy in Extensive Metastatic Patient with Advanced Non-small Cell Lung Cancer
by: Xiaoqing LIU, et al.
Published: (2009-12-01)

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
by: Isla D, et al.
Published: (2016-12-01)

Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review.
by: Xiaofeng Chen, et al.
Published: (2013-01-01)

Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
by: Yongsheng Wang, et al.
Published: (2012-01-01)

A Systematic Review of Erlotinib for Advanced Non-small Cell Lung Cancer
by: Jinhui TIAN, et al.
Published: (2009-12-01)

Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice
by: Josephine Krainhöfer, et al.
Published: (2014-01-01)

Erlotinib in the trentment of Advanced Non-small-cell Lung Cancer: A Systematic Review
by: Yanming TANG, et al.
Published: (2009-12-01)

Costs of adverse events associated with afatinib, erlotinib, and gefitinib first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations
by: Adolfo Favaretto, et al.
Published: (2017-08-01)

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
by: Karachaliou N, et al.
Published: (2014-11-01)

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
by: Enriqueta Felip, et al.
Published: (2008-06-01)

Efficacy of erlotinib as first-line maintenance therapy in patients with locally advanced or metastatic nonsmall cell lung cancer who have not experienced disease progression or unacceptable toxicity during chemotherapy
by: Senthil Rajappa, et al.
Published: (2017-01-01)

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
by: Nguyen KS, et al.
Published: (2012-09-01)

Clinical Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer
by: Haiqing YUAN, et al.
Published: (2009-07-01)

Clinical Study of Erlotinib in the Treatment of Patients with Advanced Stage Non-small Cell Lung Cancer
by: Renhua GUO, et al.
Published: (2009-12-01)

Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer and COPD
by: Huiling ZHANG, et al.
Published: (2009-12-01)

Clinical Observation of Erlotinib in the Treatment of Advanced and Previously Treated Non-small Cell Lung Cancer
by: Liyan XU, et al.
Published: (2009-12-01)

The Impact of Smoking Status on the Efficacy of Erlotinib in Patients with Advanced Non-small Cell Lung Cancer
by: Yilong WU, et al.
Published: (2009-12-01)

Our Experiences with Erlotinib in Second and Third Line Treatment Patients with Advanced Stage Iiib/ Iv Non-Small Cell Lung Cancer
by: Bakir Mehić, et al.
Published: (2008-11-01)

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung
by: Lu S, et al.
Published: (2018-11-01)

Experience with erlotinib in the treatment of non-small cell lung cancer
by: Lorenza Landi, et al.
Published: (2015-08-01)

Erlotinib for the treatment of relapsed non-small cell lung cancer
by: C McLeod, et al.
Published: (2009-06-01)

Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients
by: Cong Wang, et al.
Published: (2018-04-01)

Primary localized conjunctival amyloidosis: A case report with a ten-year follow-up period
by: Juan Carlos Mesa-Guti&eacute;rrez, et al.
Published: (2008-10-01)

Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer
by: Fang CHENG, et al.
Published: (2016-10-01)

Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review
by: Chouaïd C, et al.
Published: (2014-12-01)

PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
by: A. U. Kulikov
Published: (2015-03-01)

A Retrospective Analysis of Erlotinib and TP/GP Regimen in the Treatment of Advanced Non-small Cell Lung Cancer
by: Yongjuan WU, et al.
Published: (2009-12-01)

Clinical Observation of Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer: A Report of 92 Eases
by: Baohui HAN, et al.
Published: (2009-12-01)

Erlotinib in Patients with Brain Metastases for Non-small Cell Lung Cancer
by: Jinming YU, et al.
Published: (2009-12-01)

Progression in Therapy of Erlotinib for Patients with Non-small Cell Lung Cancer
by: Li MA, et al.
Published: (2009-12-01)

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China
by: Xiaohui Zeng, et al.
Published: (2020-11-01)

Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.
by: Paul Germonpré, et al.
Published: (2019-01-01)

Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).
by: Jacques De Grève, et al.
Published: (2016-01-01)

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01)

The Cost-effectiveness Analysis of Gefitinib or Erlotinib in the Treatment of  Advanced EGFR Mutant Non-small Cell Lung Cancer Patients
by: Yuxiang MA, et al.
Published: (2013-04-01)

Cannot write session to /tmp/vufind_sessions/sess_vo2brt9m3otconncqf1gdb3vtt